UY40025A - Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far - Google Patents

Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far

Info

Publication number
UY40025A
UY40025A UY0001040025A UY40025A UY40025A UY 40025 A UY40025 A UY 40025A UY 0001040025 A UY0001040025 A UY 0001040025A UY 40025 A UY40025 A UY 40025A UY 40025 A UY40025 A UY 40025A
Authority
UY
Uruguay
Prior art keywords
naftiridinone
disorder
disease
derivatives
treatment
Prior art date
Application number
UY0001040025A
Other languages
English (en)
Spanish (es)
Inventor
Atwood Kim Cheung
Donglei Liu
Stefan Peukert
Heng Ge
Yu Gai
Xingjuan Chang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY40025A publication Critical patent/UY40025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001040025A 2021-11-23 2022-11-17 Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far UY40025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163282492P 2021-11-23 2021-11-23
CN2022128601 2022-10-31

Publications (1)

Publication Number Publication Date
UY40025A true UY40025A (es) 2023-06-15

Family

ID=84370237

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040025A UY40025A (es) 2021-11-23 2022-11-17 Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far

Country Status (29)

Country Link
US (2) US12084442B2 (enExample)
EP (2) EP4436662B1 (enExample)
JP (1) JP7826477B2 (enExample)
KR (1) KR20240110040A (enExample)
CN (1) CN118382623A (enExample)
AR (1) AR127698A1 (enExample)
AU (1) AU2022396087A1 (enExample)
CA (1) CA3235682A1 (enExample)
CL (1) CL2024001524A1 (enExample)
CO (1) CO2024006398A2 (enExample)
CR (1) CR20240216A (enExample)
DK (1) DK4436662T3 (enExample)
DO (1) DOP2024000096A (enExample)
EC (1) ECSP24038829A (enExample)
ES (1) ES3054973T3 (enExample)
FI (1) FI4436662T3 (enExample)
HR (1) HRP20251558T1 (enExample)
IL (1) IL312689A (enExample)
JO (1) JOP20240119A1 (enExample)
LT (1) LT4436662T (enExample)
MA (1) MA67325B1 (enExample)
MX (1) MX2024006176A (enExample)
PE (1) PE20241328A1 (enExample)
PL (1) PL4436662T3 (enExample)
PT (1) PT4436662T (enExample)
RS (1) RS67492B9 (enExample)
TW (1) TW202329949A (enExample)
UY (1) UY40025A (enExample)
WO (1) WO2023094965A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260015867A (ko) * 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
HUP0301335A3 (en) 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
CN100447142C (zh) 2002-11-18 2008-12-31 诺瓦提斯公司 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP5179174B2 (ja) 2004-05-28 2013-04-10 ノバルティス ファーマ アーゲー アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
CA2568164A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006005726A2 (en) 2004-07-09 2006-01-19 Speedel Experimenta Ag Heterocyclic compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
US20090156875A1 (en) 2006-04-04 2009-06-18 Takafumi Tomioka Methane separation method, methane separation apparatus, and methane utilization system
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2660701A1 (en) 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
EA200900811A1 (ru) 2006-12-18 2009-12-30 Новартис Аг Имидазолы в качестве ингибиторов альдостеронсинтазы
KR20090090395A (ko) 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EP2094669A2 (en) 2006-12-18 2009-09-02 Novartis AG 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
RU2009139811A (ru) 2007-03-29 2011-05-10 Новартис АГ (CH) Гетероциклические спиросоединения
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2019241311A1 (en) * 2018-06-11 2019-12-19 Northeastern University Selective ligands for modulation of girk channels
KR20230022829A (ko) 2020-03-03 2023-02-16 트웬티에잇-세븐, 인크. Rna 결합 단백질 또는 rna 변형 단백질을 표적으로 하는 화합물
WO2022074567A1 (en) 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia

Also Published As

Publication number Publication date
CA3235682A1 (en) 2023-06-01
PL4436662T3 (pl) 2026-02-16
TW202329949A (zh) 2023-08-01
HRP20251558T1 (hr) 2026-01-16
KR20240110040A (ko) 2024-07-12
DOP2024000096A (es) 2024-06-30
PT4436662T (pt) 2025-12-16
US12084442B2 (en) 2024-09-10
EP4436662A1 (en) 2024-10-02
US20230203032A1 (en) 2023-06-29
MA67325B1 (fr) 2025-11-28
RS67492B9 (sr) 2026-02-27
JP7826477B2 (ja) 2026-03-09
ES3054973T3 (en) 2026-02-09
JP2024543107A (ja) 2024-11-19
IL312689A (en) 2024-07-01
EP4656240A1 (en) 2025-12-03
JOP20240119A1 (ar) 2024-05-23
AU2022396087A1 (en) 2024-04-11
CN118382623A (zh) 2024-07-23
AR127698A1 (es) 2024-02-21
PE20241328A1 (es) 2024-06-26
FI4436662T3 (fi) 2025-12-12
WO2023094965A1 (en) 2023-06-01
CO2024006398A2 (es) 2024-07-18
CL2024001524A1 (es) 2024-11-08
LT4436662T (lt) 2025-12-29
MX2024006176A (es) 2024-06-11
CR20240216A (es) 2024-07-01
ECSP24038829A (es) 2024-06-28
DK4436662T3 (da) 2025-12-22
US20250214989A1 (en) 2025-07-03
RS67492B1 (sr) 2025-12-31
EP4436662B1 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
DOP2022000117A (es) Inhibidores de kras g12c
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2023001738A1 (es) Inhibidores de prmt5
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CO2025013134A2 (es) Inhibidores de kras
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
MX2021011606A (es) Compuestos dirigidos a prmt5.
ECSP19041050A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CL2025002615A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
MX2021008213A (es) Derivados de (2,5-dioxopirrolidina-1-il)(fenil)-acetamida y su uso en el tratamiento de enfermedades neurologicas.
ECSP24038829A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
ECSP23088732A (es) Moduladores de trex1
CL2023002052A1 (es) Derivados de pirazolamida
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
ECSP23075535A (es) Compuestos cíclicos y métodos de uso